Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

It was not logic. It was a judgement (based on logic) and, considering the variables of the case of K-OC, one I stand by. I don't see the business sense in BP spending, perhaps, millions to buy K-OC and hundreds of millions more to develop a drug that as yet only has shown promise in the lab and a P-2 clinical trial comprised of 2 participants.

This is a unique case where the factors, IMO, suggest BP has better places to put its money. Again, I stand by that and I hope I'm wrong.

Message in reply to:
By your logic no BP would never license anything for ovarian cancer from smaller companies?

A quick search for "ovarian cancer preclinical license agreement" found this update of a deal between Merck and Agenus from Nov 2020:
An Agenus-discovered first-in-class ILT4 antibody, MK-4830, enters Phase 2

A $10 mio milestone payment for entering phase 2. Plus Agenus is eligible for up to an additional $85 million in milestones plus royalties on sales. Of course, the deal itself certainly brought in a couple of millions.

Sure, Ipix could never develop Kevetrin alone. But license it to BP at this stage is everyday-business and far from being a pipe dream.